XML 89 R52.htm IDEA: XBRL DOCUMENT v3.24.0.1
Acquisitions, Research Collaborations and Licensing Agreements - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details)
$ in Millions
1 Months Ended
Nov. 30, 2021
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Nov. 19, 2021
USD ($)
Business Acquisition [Line Items]          
Goodwill   $ 21,197 $ 21,204 $ 21,264  
Acceleron Pharma Inc.          
Business Acquisition [Line Items]          
Cash and cash equivalents         $ 340
Investments         285
IPR&D - sotatercept         6,380
Product rights - Reblozyl (12 year useful life)         3,830
Estimated useful life of intangible assets, acquired 12 years        
Deferred income tax liabilities, net         (1,814)
Other assets and liabilities, net         82
Total identifiable net assets         9,103
Goodwill         2,411
Consideration transferred         $ 11,514
Acceleron Pharma Inc. | Measurement Input, Discount Rate          
Business Acquisition [Line Items]          
Present value discount rate         0.075
Discount rate         0.060